An observational study in Corynebacterium Diphtheriae Infection, sponsored by Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer. Completed at 42 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-10.
Sponsored by Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer · Observational
Toxigenic cutaneous diphtheria is a notifiable disease that is re-emerging in the world and particularly in France. A better description of the epidemiological characteristics, as well as a refinement of the clinical characteristics of patients with cutaneous diphtheria, are essential to better understand this pathology, which has important public health issues and whose diagnosis absence can have catastrophic consequences for the patient and their contacts. Microbiological data (species identification, toxigenicity or not, resistance profile...) will be transmitted by the national reference center for corynebacteria of the diphtheriae complex and then caregivers who have managed the corresponding patients with cutaneous diphtheria will be contacted.
Study population corresponds to all metropolitan French patients suffering from cutaneous diphtheria for which microbiological data were registered between 2018 and 2022 by the National Reference Center for corynebacteria of the diphteriae complex.
Exclusion Criteria:
- Patient opposition
The study group consists of all the patients suffering from cutaneous diphtheria in metropolitan France and for which microbiological data were registered by the National Reference Center fo corynebacteria of the diphteriae complex between 2018 and 2022.
Other: Characteristics description
Caregivers who follow the patients of the study group will be contacted to collect these patients clinical and epidemiological characteristics
Patients epidemiological data description
Epidemiological data will be collected to describe the studied population (age, sex, place of birth, vaccination status...)
Time frame: 3 months
Patients clinical data description
Clinical data will be collected to describe the studied population (history, description of lesions, disease evolution, complications...)
Time frame: 3 months
Patients microbiological data description
Microbiological data will be collected to describe the studied population (species identification, toxigenicity, presence of a co-infection...)
Time frame: 3 months
Patients therapeutic data description
Therapeutic data will be collected to describe the studied population (antibiotic therapy, duration of treatment, search for an eradication a posteriori...)
Time frame: 3 months
Comparison of antibiotic therapy duration to national recommendations issued by the High Committee of Public Health
Duration of antibiotic therapy implemented by clinicians will be compared to national recommendations
Time frame: 3 months
Comparison of immunization status monitoring to national recommendations issued by the High Committee of Public Health
Monitoring of immunization status or not will be collected
Time frame: 3 months
Comparison of patient post infection vaccination status to national recommendations issued by the High Committee of Public Health
Post-infection vaccination or not will be collected
Time frame: 3 months
Comparison of patient microbiological follow-up to national recommendations issued by the High Committee of Public Health
Microbiological follow-up with eradication research or not will be collected.
Time frame: 3 months
Comparison of post-infection serological sampling to national recommendations issued by the High Committee of Public Health
Whether a post-infection serological sampling was performed or not will be collected.
Time frame: 3 months
Comparison of patient isolation procedures to national recommendations issued by the High Committee of Public Health
Patient isolation or not will be collected.
Time frame: 3 months
Plan to share: No
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer